Apparatus and method for transdermal delivery of epoetin-based agents

• US 20060182789A1
• Filed: 02/15/2006
• Published: 08/17/2006
• Est. Priority Date: 02/16/2005
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Maa, Yuh-Fun, Ameri, Mahmoud, Daddona, Peter, Cormier, Michel J.N.
• Application Number:
  US11/355,856
• Publication Number:
  US 20060182789A1
• Time in Patent Office: Days
• US Class Current: 424/448
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/0046 Solid microneedles
• CPC Class Codes: A61M 37/0015 by using microneedles
• CPC Class Codes: A61P 7/06 Antianaemics

Abstract

An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, an Epoetin-based agent is contained in a biocompatible coating that is applied to the microprojection member. In a further embodiment, the delivery system includes a gel pack having an Epoetin-based agent-containing hydrogel formulation that is disposed on the microprojection member after application to the skin of a patient. In an alternative embodiment, the Epoetin-based agent is contained in both the coating and the hydrogel formulation.

Claims

1. A delivery system for transdermally delivering an Epoetin-based agent to a patient, comprising:

a microprojection member having a plurality of microprojections that are adapted to pierce the stratum corneum of the patient; and

a biocompatible coating disposed on said microprojection member, said coating being formed from a coating formulation having at least one Epoetin-based agent disposed therein.

2. The delivery system of claim 1, wherein said coating is disposed on at least one of said plurality of microprojections.

3. The delivery system of claim 1, wherein said coating formulation comprises an aqueous formulation.

4. The delivery system of claim 1, wherein said coating formulation comprises a non-aqueous formulation.

5. The delivery system of claim 1, wherein said Epoetin-based agent is selected from the group consisting of Epoetin alpha, Epoetin beta, darbepoetin alfa, and pharmaceutically acceptable salts, analogs, simple derivatives, closely related molecules and combinations thereof.

6. The delivery system of claim 5, wherein said Epoetin-based agent comprises Epoetin alpha.

7. The delivery system of claim 1, wherein said Epoetin-based agent comprises in the range of approximately 1-30 wt. % of said coating formulation.

8. The delivery system of claim 1, wherein the coating on the microprojection member comprises a dose of Epoetin-based agent in the range of about 15 to 200 μ

g.

9. The delivery system of claim 1, wherein the pH of said coating formulation is below approximately pH 4.5 or above approximately pH 5.

10. The delivery system of claim 1, wherein said coating formulation includes at least one buffer selected from the group consisting of ascorbic acid, citric acid, succinic acid, glycolic acid, gluconic acid, glucuronic acid, lactic acid, malic acid, pyruvic acid, tartaric acid, tartronic acid, fumaric acid, maleic acid, phosphoric acid, tricarbally acid, malonic acid, adipic acid, citraconic acid, glutaratic acid, itaconic acid, mesaconic acid, citramalic acid, dimethylopropionic acid, tiglic acid, glyceric acid, methacrylic acid, isocrotonic acid, 0-hydroxybutyric acid, crotonic acid, angelic acid, hydracrylic acid, aspartic acid, glutamic acid, glycine and mixtures thereof.

11. The delivery system of claim 1, wherein said coating formulation includes at least one surfactant selected from the group consisting of sodium lauroamphoacetate, sodium dodecyl sulfate (SDS), cetylpyridinium chloride (CPC), dodecyltrimethyl ammonium chloride (TMAC), benzalkonium, chloride, polysorbates, sorbitan derivatives, alkoxylated alcohols and mixtures thereof.

12. The delivery device of claim 1, wherein said coating formulation includes at least one counterion to neutralize the charge of the Epoetin-based agent.

13. The delivery system of claim 1, wherein said coating formulation includes a hydrophilic polymer selected from the following group consisting of hydroxyethyl starch, dextran, poly(vinyl alcohol), poly(ethylene oxide), poly(2-hydroxyethyl-methacrylate), poly(n-vinyl pyrolidone), polyethylene glycol and mixtures thereof.

14. The delivery system of claim 1, wherein said coating formulation includes a biocompatible carrier selected from the group consisting of human albumin, bioengineered human albumin, polyglutamic acid, polyaspartic acid, polyhistidine, pentosan polysulfate, polyamino acids, sucrose, trehalose, melezitose, raffinose, stachyose, mannitol and like sugar alcohols.

15. The delivery system of claim 1, wherein said coating formulation includes a stabilizing agent selected from the group consisting of a non-reducing sugar, a polysaccharide and a reducing sugar.

16. The delivery system of claim 1, wherein said coating formulation includes at least one vasoconstrictor selected from the group consisting of amidephrine, cafaminol, cyclopentaimine, deoxyepinephrine, epinephrine, felypressin, indanzoline, metizoline, midodrine, naphazoline, nordefrin, octodrine, ornipressin, oxymethazoline, phenylephrine, phenylethanolamine, phenylpropanolamine, propylhexedrine, pseudoephedrine, tetrahydrozoline, tramazoline, tuaminoheptane, tymazoline, vasopressin, xylometazoline, and mixtures thereof.

17. The delivery system of claim 1, wherein said coating formulation includes at least one pathway patency modulator selected from the group consisting of osmotic agents, zwitterionic compounds, anti-inflammatory agents and anticoagulants.

18. The delivery system of claim 1, wherein said coating formulation includes a solubilising/complexing agent selected from the group consisting of Alpha-Cyclodextrin, Beta-Cyclodextrin, Gamma-Cyclodextrin, glucosyl-alpha-Cyclodextrin, maltosyl-alpha-Cyclodextrin, hydroxyethyl-beta-Cyclodextrin, methyl-beta-Cyclodextrin, sulfobutylether-alpha-Cyclodextrin, sulfobutylether-beta-Cyclodextrin, and sulfobutylether-gamma-Cyclodextrin.

19. A delivery system for transdermally delivering a Epoetin-based agent to a patient, comprising:

a microprojection member having a plurality of microprojections that are adapted to pierce the stratum corneum of the patient; and

a hydrogel formulation having at least one Epoetin-based agent, said hydrogel formulation being in communication with said microprojection member.

20. The delivery system of claim 19, wherein said Epoetin-based agent comprises in the range of approximately 1 to 30 wt. % of the hydrogel formulation.

21. The delivery system of claim 19, wherein said Epoetin-based agent is selected from the group consisting of Epoetin alpha, Epoetin beta, darbepoetin alfa, and pharmaceutically acceptable salts, analogs, simple derivatives, closely related molecules and combinations thereof.

22. The delivery system of claim 19, wherein said Epoetin-based agent comprises Epoetin alpha.

23. The delivery system of claim 19, wherein the pH of said hydrogel formulation is below approximately pH 4.5 or above approximately pH5.

24. The delivery system of claim 19, wherein said hydrogel formulation comprises a water-based hydrogel having a macromolecular polymeric network.

25. The delivery system of claim 19, wherein said hydrogel formulation includes at least one surfactant, selected from the group consisting of sodium lauroamphoacetate, sodium dodecyl sulfate (SDS), cetylpyridinium chloride (CPC), dodecyltrimethyl ammonium chloride (TMAC), benzalkonium, chloride, polysorbates, sorbitan derivatives, and alkoxylated alcohols.

26. A delivery system for transdermally delivering a Epoetin-based agent to a patient;

comprising;

a microprojection member having a plurality of microprojections that are adapted to pierce the stratum corneum of the patient;

a solid state formulation disposed proximate said microprojection member; and

a hydrogel formulation, said hydrogel formulation adapted to communicate with said solid state formulation.

27. The delivery system of claim 26, wherein said solid state formulation is a solid film made by casting a liquid formulation comprising at least one Epoetin-based agent, a polymeric material, a plasticizing agent, a surfactant and a volatile solvent.

28. The delivery system of claim 27, wherein said liquid formulation comprises 1-30 wt. % Epoetin-based agent, 5-40 wt. % polymer, 5-40 wt. % plasticizer, 0-2 wt. % surfactant, and the balance comprising volatile solvent.

29. The delivery system of claim 26, wherein the pH of said liquid formulation is below approximately pH4.5 or above approximately pH 5.

30. A method of transdermally delivering a Epoetin-based agent to a patient, comprising the steps of:

providing a microprojection member having a plurality of microprojections, said microprojection member having a coating disposed thereon, said coating including at least one Epoetin-based agent;

applying said microprojection member to a skin site of said patient, whereby said plurality of microprojections pierce the stratum corneum and deliver said Epoetin-based agent to said patient; and

removing said microprojection member from said skin site.

31. The method of claim 30, wherein said microprojection member remains applied to said skin site for a period of time in the range of 5 sec. to 24 hrs.

32. The method of claim 30, wherein said Epoetin-based agent is selected from the group consisting of Epoetin alpha, Epoetin beta, darbepoetin alfa, and pharmaceutically acceptable salts, analogs, simple derivatives, closely related molecules and combinations thereof.

33. The method of claim 30, wherein said Epoetin-based agent comprises Epoetin alpha.

34. The method of claim 30, wherein said Epoetin-based agent comprises in the range of approximately 15 μ

g-200 μ

g of said biocompatible coating.

35. The method of claim 30, wherein said delivery of said Epoetin-based agent exhibits improved pharmacokinetics compared to the pharmacokinetic characteristics of subcutaneous delivery.

36. A method for transdermally delivering a Epoetin-based agent to a patient, comprising the steps of:

providing a microprojection assembly having a microprojection member and a gel pack, said microprojection member including a plurality of microprojections, said gel pack including a hydrogel formulation having at least one Epoetin-based agent;

applying said microprojection member to a skin site of said patient, whereby a plurality of microslits are formed in the patient'"'"'s stratum-corneum;

placing said gel pack on said microprojection member, whereby said hydrogel formulation is released from said gel pack and migrates into and through said microslits formed by said microprojections; and

removing said microprojection member from said skin site.

37. The method of claim 36, wherein said gel pack includes a release liner and said method includes the step of removing said release liner prior to placing said gel pack on said microprojection member.

38. The method of claim 36, wherein said microprojection member includes a biocompatible coating having at least one Epoetin-based agent.

39. The method of claim 36, wherein said microprojection member remains applied to said skin site for a period of time in the range of 5 min. to 24 hrs.

40. The method of claim 36, wherein said Epoetin-based agent is selected from the group consisting of Epoetin alpha, Epoetin beta, darbepoetin alfa, and pharmaceutically acceptable salts, analogs, simple derivatives, closely related molecules and combinations thereof.

41. The method of claim 36, wherein said Epoetin-based agent comprises Epoetin alpha.

42. The method of claim 36, wherein said Epoetin-based agent comprises in the range of approximately 1-30 wt. % of said hydrogel formulation.

43. The method of claim 36, wherein said delivery of said Epoetin-based agent exhibits improved pharmacokinetics compared to the pharmacokinetic characteristics of subcutaneous delivery.

44. A method for transdermally delivering a Epoetin-based agent to a patient, comprising the steps of:

providing a microprojection assembly having a microprojection member and a gel pack, said microprojection member including a plurality microprojections, said microprojection member further including a biocompatible coating having at least one Epoetin-based agent, said gel pack including a hydrogel formulation;

applying said microprojection member to a skin site of said patient, whereby a plurality of microslits are formed in the patient'"'"'s stratum-corneum;

placing said gel pack on said microprojection member, whereby said hydrogel formulation is released from said gel pack and migrates into and through said microslits formed by said microprojections; and

removing said microprojection member from said skin site.

45. The method of claim 44, wherein said gel pack includes a release liner and said method includes the step of removing said release liner prior to placing said gel pack on said microprojection member.

46. The method of claim 44, wherein said microprojection member remains applied to said skin site for a period of time in the range of 5 min. to 24 hrs.

47. The method of claim 44, wherein said Epoetin-based agent is selected from the group consisting of Epoetin alpha, Epoetin beta, darbepoetin alfa, and pharmaceutically acceptable salts, analogs, simple derivatives, closely related molecules and combinations thereof.

48. The method of claim 44, wherein said Epoetin-based agent comprises in the range of approximately 15 μ

g-200 μ

g of said biocompatible coating.

49. The method of claim 44, wherein said Epoetin-based agent comprises Epoetin alpha.

50. The method of claim 44, wherein said delivery of said Epoetin-based agent exhibits improved pharmacokinetics compared to pharmacokinetics characteristic of subcutaneous delivery.

51. A method for transdermally delivering a Epoetin-based agent to a patient, comprising the steps of:

providing a microprojection assembly having a microprojection member, a gel pack and a solid state formulation, said microprojection member including a plurality of microprojections, said gel pack including a hydrogel formulation, said solid state formulation being disposed proximate said microprojection member and including at least one Epoetin-based agent;

applying said microprojection member to a skin site of said patient, whereby a plurality of microslits are formed in the patient'"'"'s stratum-corneum;

placing said gel pack on said microprojection member, whereby said hydrogel formulation is released from said gel pack and migrates into and through said microslits formed by said microprojections; and

removing said microprojection member from said skin site.

52. The method of claim 51, wherein said gel pack includes a release liner and said method includes the step of removing said release liner prior to placing said gel pack on said microprojection member.

53. The method of claim 51, wherein said microprojection member remains applied to said skin site for a period of time in the range of 5 min. to 24 hrs.

54. The method of claim 51, wherein said Epoetin-based agent is selected from the group consisting of Epoetin alpha, Epoetin beta, darbepoetin alfa, and pharmaceutically acceptable salts, analogs, simple derivatives, closely related molecules and combinations thereof.

55. The method of claim 51, wherein said solid state formulation is formed from a liquid formulation having in the range of about 1-30 wt. % of said Epoetin-based agent.

56. The method of claim 51, wherein said Epoetin-based agent comprises Epoetin alpha.

57. The method of claim 51, wherein said delivery of said Epoetin-based agent exhibits improved pharmacokinetics compared to the pharmacokinetic characteristics of subcutaneous delivery.